← FDA DRUG APPROVALS

FDA ANDA · ANDA077477

BETAMETHASONE DIPROPIONATE

Sponsor: SUN PHARMA CANADA

APPLICATION
ANDA077477
TYPE
ANDA
ORIGINAL APPROVAL
2007-05-21
LATEST ACTION
2020-06-15
ROUTE
TOPICAL
DOSAGE FORM
LOTION, AUGMENTED
MARKETING STATUS
Prescription

Products

BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · LOTION, AUGMENTED · TOPICAL

Approval history

2020-06-15Labeling · Supplement 9 · standardAP
2015-07-15Labeling · Supplement 7 · standardAP
2011-03-30Labeling · Supplement 3AP
2007-05-21OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →